Technical Assistance - Siemens Immulite Homocysteine 2000 User Manual

factor for vascular disease. New Eng J Med
1991;324:1149-55. 5) Deloughery TG, Evans A,
Sadeghi A,et al. Common mutation in
methylenetetrahydrofolate reductase:
Correlation with homocysteine metabolism and
late-onset vascular disease. Circulation
1996;94:3074-78. 6) Bostom AG, Selhub J.
Homocysteine and arteriosclerosis: Subclinical
and clinical disease associations. Circulation
1999;99:2361-63. 7) Boushey CJ, Beresford
SAA, et al. A quantitative assessment of plasma
homocysteine as a risk factor for vascular
disease. JAMA 1995;274(13):1049-57. 8)
Guttormsen AB, Svarstad E, et al. Elimination of
homocysteine in subjects with end-stage renal
failure. Irish J Med Sci 1995;164:8. 9) Bostom
AG, Lathrop, L. Hyper-homocysteinemia in end-
stage renal disease (ESDR): Prevalence,
etiology and potential relationship to arterio-
sclerotic outcomes. Kidney Int 1997;52:10-20.
10) Refsum H, Ueland PM. Clinical significance
of pharmacological modulation of homocysteine
metabolism. TIPS 1990;11:411-16. 11) Ueland
PM, Refsum H, Stabler SP, et al. Total
homocysteine in plasma or serum: Methods and
clinical applications. Clin Chem 1993;39:1764-
79. 12) Nehler MR, Taylor LM, Porter JM.
Homocysteine as a risk factor for
atherosclerosis: A Review. Cardiovasc Pathol
1997;6:1-9.

Technical Assistance

In the United States, contact Siemens
Medical Solutions Diagnostics Technical
Services department.
Tel: 800.372.1782 or 973.927.2828
Fax: 973.927.4101. Outside the United
States, contact your National Distributor.
The Quality System of Siemens Medical
Solutions Diagnostics is certified to
ISO 13485:2003.
Tables and Graphs
Precision (µmol/L)
Within-Run
3 4
Mean SD
1 3.94 0.29
2 9.88 0.47
3 11.1 0.38
4 25.9 1.06
6
1 2
Total
5
CV SD CV
7.4% 0.41 10.4%
4.8% 0.75 7.6%
3.4% 0.46 4.1%
4.1% 1.31 5.1%
Specificity (µmol/L)
1
Compound
Adenosine
S-adenosyl-L-methionine
Cystathionine
L-Cysteine
Glutathione
ND: Not detectable.
Linearity (µmol/L)
1
Dilution Observed
5
1 8 in 8 19.2
4 in 8 9.47
2 in 8 4.94
1 in 8 2.11
2 8 in 8 25.2
4 in 8 13.8
2 in 8 6.15
1 in 8 3.34
3 8 in 8 31.6
4 in 8 15.7
2 in 8 7.44
1 in 8 3.37
4 8 in 8 47.5
4 in 8 24.2
2 in 8 11.5
1 in 8 4.91
Recovery (µmol/L)
1
Solution Observed
1 — 7.41
A 13.3
B 20.2
C 34.4
2 — 9.96
A 14.7
B 22.6
C 36.2
3 — 13.3
A 16.9
B 26.0
C 32.0
IMMULITE 2000 Homocysteine (PIL2KHO-14, 2007-11-20)
Amount
2
Added % Cross
µmol/L reactivity
5000
500 0.6%
500 6.1%
100000
100000
4
2 3
Expected %O/E
—
9.60 99%
4.80 103%
2.40 88%
—
12.6 110%
6.30 98%
3.15 106%
—
15.8 99%
7.90 94%
3.95 85%
—
23.7 102%
11.9 97%
5.94 83%
2 3
Expected %O/E
—
13.3 100%
19.5 104%
32.0 108%
—
15.7 94%
22.0 103%
34.5 105%
—
18.9 89%
25.1 104%
37.6 85%
3
ND
ND
ND
4
—
—
—
—
4
—
—
—